Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 804043, 9 pages
http://dx.doi.org/10.1155/2012/804043
Clinical Study

Antiviral Treatment Alters the Frequency of Activating and Inhibitory Receptor-Expressing Natural Killer Cells in Chronic Hepatitis B Virus Infected Patients

1Department of Hepatology, The First Hospital, Jilin University, Changchun 130021, China
2Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei 230027, China
3Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
4Institute of Infection, Immunity and Inflammation, University of Glasgow, G12 8TA, UK

Received 13 August 2012; Revised 4 October 2012; Accepted 15 November 2012

Academic Editor: Alex Kleinjan

Copyright © 2012 Juan Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. F. Liaw and C. M. Chu, “Hepatitis B virus infection,” The Lancet, vol. 373, no. 9663, pp. 582–592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Peters, H. W. Hann, P. Martin et al., “Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B,” Gastroenterology, vol. 126, no. 1, pp. 91–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. E. I. Rigopoulou, D. Suri, S. Chokshi et al., “Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity,” Hepatology, vol. 42, no. 5, pp. 1028–1036, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. H. Chen, J. H. Wang, C. M. Lee et al., “Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil,” Antiviral Therapy, vol. 11, no. 6, pp. 771–778, 2006. View at Google Scholar · View at Scopus
  5. Y. S. Lee, D. J. Suh, Y. S. Lim et al., “Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy,” Hepatology, vol. 43, no. 6, pp. 1385–1391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. F. Liaw, C. M. Lee, R. N. Chien, and C. T. Yeh, “Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis,” Journal of Viral Hepatitis, vol. 13, no. 4, pp. 250–255, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. K. Parvez, D. Sehgal, S. Jameel, S. K. Sarin, and S. F. Basir, “Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-γ,” World Journal of Gastroenterology, vol. 12, no. 18, pp. 3006–3014, 2006. View at Google Scholar · View at Scopus
  8. P. Marcellin, O. Lada, and T. Asselah, “Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine,” Hepatology Research, vol. 37, supplement 1, pp. S55–S61, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. G. V. Matthews, D. A. Cooper, and G. J. Dore, “Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir,” Antiviral Therapy, vol. 12, no. 1, pp. 119–122, 2007. View at Google Scholar · View at Scopus
  10. I. Rapti, E. Dimou, P. Mitsoula, and S. J. Hadziyannis, “Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B,” Hepatology, vol. 45, no. 2, pp. 307–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Stephan, B. Dauer, P. Khaykin et al., “Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?” Current HIV Research, vol. 7, no. 3, pp. 320–326, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Marcellin, E. J. Heathcote, M. Buti et al., “Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B,” New England Journal of Medicine, vol. 359, no. 23, pp. 2442–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. V. J. Cavanaugh, L. G. Guidotti, and F. V. Chisari, “Interleukin-12 inhibits hepatitis B virus replication in transgenic mice,” Journal of Virology, vol. 71, no. 4, pp. 3236–3243, 1997. View at Google Scholar · View at Scopus
  14. N. V. Naoumov and S. Rossol, “Studies of interleukin-12 in chronic hepatitis B virus infection,” Journal of viral hepatitis, vol. 4, supplement 2, pp. 87–91, 1997. View at Google Scholar · View at Scopus
  15. F. V. Chisari, “Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B,” American Journal of Pathology, vol. 156, no. 4, pp. 1117–1132, 2000. View at Google Scholar · View at Scopus
  16. C. Boni, A. Penna, G. S. Ogg et al., “Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy,” Hepatology, vol. 33, no. 4, pp. 963–971, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Thimme, S. Wieland, C. Steiger et al., “CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection,” Journal of Virology, vol. 77, no. 1, pp. 68–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Rijckborst, M. J. Sonneveld, and H. L. A. Janssen, “Review article: chronic hepatitis B—anti-viral or immunomodulatory therapy?” Alimentary Pharmacology and Therapeutics, vol. 33, no. 5, pp. 501–513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. N. Stoop, R. G. van der Molen, E. J. Kuipers, J. G. Kusters, and H. L. A. Janssen, “Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B,” Virology, vol. 361, no. 1, pp. 141–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Cooksley, S. Chokshi, Y. Maayan et al., “Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 312–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Jiang, W. Li, L. Yu et al., “Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies,” Cellular and Molecular Immunology, vol. 8, no. 1, pp. 75–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Trehanpati, S. Kotillil, S. S. Hissar et al., “Circulating tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate,” Journal of Clinical Immunology, vol. 31, no. 3, pp. 509–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Boni, A. Penna, A. Bertoletti et al., “Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B,” Journal of Hepatology, vol. 39, no. 4, pp. 595–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. U. Mondelli, S. Varchetta, and B. Oliviero, “Natural killer cells in viral hepatitis: facts and controversies,” European Journal of Clinical Investigation, vol. 40, no. 9, pp. 851–863, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. J. M. Webster, S. Reignat, M. K. Maini et al., “Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms,” Hepatology, vol. 32, no. 5, pp. 1117–1124, 2000. View at Google Scholar · View at Scopus
  26. B. Gao, W. I. Jeong, and Z. Tian, “Liver: an organ with predominant innate immunity,” Hepatology, vol. 47, no. 2, pp. 729–736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Yamagiwa, H. Kamimura, and T. Ichida, “Natural killer cell receptors and their ligands in liver diseases,” Medical Molecular Morphology, vol. 42, no. 1, pp. 1–8, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari, “Viral clearance without destruction of infected cells during acute HBV infection,” Science, vol. 284, no. 5415, pp. 825–829, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Fisicaro, C. Valdatta, C. Boni et al., “Early kinetics of innate and adaptive immune responses during hepatitis B virus infection,” Gut, vol. 58, no. 7, pp. 974–982, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Chen, H. Wei, R. Sun, Z. Dong, J. Zhang, and Z. Tian, “Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells,” Hepatology, vol. 46, no. 3, pp. 706–715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Dunn, M. Brunetto, G. Reynolds et al., “Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage,” Journal of Experimental Medicine, vol. 204, no. 3, pp. 667–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. E. T. Tjwa, G. W. Van Oord, J. P. Hegmans, H. L. A. Janssen, and A. M. Woltman, “Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B,” Journal of Hepatology, vol. 54, no. 2, pp. 209–218, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Peppa, L. Micco, A. Javaid et al., “Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection,” PLoS Pathogens, vol. 6, no. 12, Article ID e1001227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Brook, V. Soriano, and C. Bergin, “European guideline for the management of hepatitis B and C virus infections, 2010,” International Journal of STD and AIDS, vol. 21, no. 10, pp. 669–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Zou, D. Xu, B. Li et al., “Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure,” Hepatology Research, vol. 39, no. 12, pp. 1198–1207, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Pelletier, C. Drouin, N. Bédard, S. I. Khakoo, J. Bruneau, and N. H. Shoukry, “Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses,” Journal of Hepatology, vol. 53, no. 5, pp. 805–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Ota, K. Takeda, H. Akiba et al., “IFN-γ-mediated negative feedback regulation of NKT-cell function by CD94/NKG2,” Blood, vol. 106, no. 1, pp. 184–192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Caligiuri, “Human natural killer cells,” Blood, vol. 112, no. 3, pp. 461–469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Bonorino, M. Ramzan, X. Camous et al., “Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C,” Journal of Hepatology, vol. 51, no. 3, pp. 458–467, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Oliviero, S. Varchetta, E. Paudice et al., “Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections,” Gastroenterology, vol. 137, no. 3, pp. 1151–1160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Scott-Algara, M. Mancini-Bourgine, H. Fontaine, S. Pol, and M. L. Michel, “Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination,” PLoS One, vol. 5, no. 1, Article ID e8761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. R. J. Harrison, A. Ettorre, A. M. Little, and S. I. Khakoo, “Association of NKG2A with treatment for chronic hepatitis C virus infection,” Clinical and Experimental Immunology, vol. 161, no. 2, pp. 306–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Amadei, S. Urbani, A. Cazaly et al., “Activation of natural killer cells during acute infection with hepatitis C virus,” Gastroenterology, vol. 138, no. 4, pp. 1536–1545, 2010. View at Publisher · View at Google Scholar · View at Scopus